Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.71 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.70 |
| ▸ | BCHE | P06276 | 2/20 | 0.70 |
| ▸ | CNR2 | P34972 | 4/20 | 0.63 |
| ▸ | CNR1 | P21554 | 3/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.63 |
| ▸ | MLNR | O43193 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | PDE9A | O76083 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472463 | 1.00 | OPRM1 (0.71) | OPRM1ACE2BCHECNR2CNR1 | |
| SCHEMBL19472331 | 0.94 | BCHE (0.79) | OPRM1BCHECNR2CNR1TRPV1 | |
| SCHEMBL7859647 | 0.94 | BCHE (0.79) | OPRM1BCHECNR2CNR1TRPV1 | |
| SCHEMBL16404764 | 0.94 | BCHE (0.66) | OPRM1ACE2BCHE | |
| SCHEMBL16907964 | 0.94 | OPRM1 (0.64) | OPRM1ACE2BCHECNR2CNR1 | |
| SCHEMBL8032251 | 0.92 | OPRM1 (0.68) | OPRM1ACE2BCHECNR2CNR1 | |
| SCHEMBL13472477 | 0.92 | OPRM1 (0.68) | OPRM1ACE2BCHECNR2CNR1 | |
| SCHEMBL7849313 | 0.90 | OPRM1 (0.79) | OPRM1ACE2BCHECNR2CNR1 | |
| SCHEMBL12830395 | 0.90 | OPRM1 (0.66) | OPRM1ACE2BCHECNR2CNR1 | |
| SCHEMBL21775926 | 0.89 | OPRM1 (0.73) | OPRM1ACE2BCHECNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298399-A1 | BIOSYNTHESIS OF CANNABINOID PRODRUGS AND THEIR USE AS THERAPEUTIC AGENTS | TUATARA CAPITAL FUND I, L.P. | 2017-10-19 | — | — | US | disclosed |
| US-20170298399-A1 | BIOSYNTHESIS OF CANNABINOID PRODRUGS AND THEIR USE AS THERAPEUTIC AGENTS | TUATARA CAPITAL FUND I, L.P. | 2017-10-19 | — | — | US | disclosed |
| US-9533942-B2 | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles | ZYNERBA PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-8293786-B2 | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same | ALLTRANZ INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293786-B2 | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same | ALLTRANZ INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011026144-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2010126501-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND METHODS FOR THEIR USE | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127033-A1 | FORMULATIONS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273895-A1 | FORMULATIONS OF CANNABIDIOL AND PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273895-A1 | FORMULATIONS OF CANNABIDIOL AND PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OPRM1 101/4885ACE2 1763/4885BCHE 239/4885 |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | OPRM1 35/4885ACE2 2368/4885BCHE 166/4885 |
| US-20170298399-A1 | BIOSYNTHESIS OF CANNABINOID PRODRUGS AND THEIR USE AS THERAPEUTIC AGENTS | CNR2, CNR1, FAAH | OPRM1 184/4885ACE2 1681/4885BCHE 336/4885 |
| US-20120202891-A1 | Cannabinoid-Containing Compositions and Methods for Their Use | CNR2, CNR1, FAAH | OPRM1 465/4885ACE2 1881/4885BCHE 1507/4885 |
| US-20100273895-A1 | FORMULATIONS OF CANNABIDIOL AND PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | OPRM1 103/4885ACE2 1776/4885BCHE 129/4885 |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | OPRM1 35/4885ACE2 2368/4885BCHE 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.